- Home
- SOTK vs MAIA Comparison
SOTK vs MAIA Comparison
Compare SOTK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOTK | MAIA |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 89.7M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SOTK | MAIA |
|---|---|---|
| Price | $3.98 | $1.38 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.7K | ★ 1.1M |
| Earning Date | 01-13-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,504,381.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $50.50 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $3.23 | $0.87 |
| 52 Week High | $5.15 | $3.19 |
Technical Indicators
Market Signals| Indicator | SOTK | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 34.56 |
| Support Level | $3.89 | $1.26 |
| Resistance Level | $4.34 | $1.74 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 33.79 | 2.22 |
Price Performance
Historical ComparisonAbout SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.